Skip to main content

EMA’s regulatory perspective on biosimilars: challenges, problems, new tools

By 19 Aprile 2019Maggio 12th, 2021No Comments
CongressiSpeciali

We talked about EMA’s regulatory perspective on biosimilars: challenges, problems, new tools with Thijs Giezen (Ziekenhuisapotheker SAHZ, Haarlem), consulent for European Medicines Agency (EMA), met during ISPE’S 2019 Mid-Year Meeting, in Rome.